NLRP3
BGE-102: oral CNS-penetrant NLRP3 inhibitor
Lead indication: obesity
NLRP3 is a critical component of the inflammasome. Chronic inflammasome activation results in inflammation that drives metabolic and neuroinflammatory diseases.
BioAge has discovered a family of chemically novel NLRP3 inhibitors well positioned to address these diseases given:
• High potency (low single-digit nanomolar in human microglia, the target cells in the brain)
• High CNS penetration (~1 brain/plasma)
• Selective & reversible inhibition
BGE-102, a CNS-penetrant NLRP3 inhibitor is our lead program. We anticipate IND submission in mid-2025 and if accepted, Phase 1 SAD data by 2025 year end.
(CNS penetrant)
(CNS penetrant)
(CNS penetrant)
(CNS penetrant)
We have discovered structurally and mechanistically novel inhibitors that bind in a distinct region of NLRP3
Peripheral inflammation and neuroinflammation are key drivers of obesity.
Our inhibitors have the potential to address both
Peripheral and neuroinflammation are key
drivers of obesity. Our inhibitors have the
potential to address both
Peripheral and neuroinflammation
are key drivers of obesity. Our
inhibitors have the potential to
address both
Peripheral inflammation and neuroinflammation are key drivers of obesity.
Our inhibitors have the potential to address both
Peripheral and neuroinflammation are key
drivers of obesity. Our inhibitors have the
potential to address both
Peripheral and neuroinflammation
are key drivers of obesity. Our
inhibitors have the potential to
address both
